HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.

Abstract
EM-652 exerts pure antiestrogenic activity in the mammary gland and endometrium, while tamoxifen, the antiestrogen most widely used for the treatment of breast cancer, exerts mixed antiestrogenic-estrogenic activity in these tissues. Our objective was to compare the agonistic and antagonistic effects of EM-652 with tamoxifen and 5 other antiestrogens on the growth of ZR-75-1 human breast xenografts in ovariectomized nude mice. During the 23 weeks of treatment at a daily oral dose of 50 microg, EM-652 was the only compound that decreased tumor size relative to pretreatment values, whereas the 6 other antiestrogens only decreased to various extents the progression rate stimulated by estrone. Under estrone stimulation, all groups of animals had more than 60% of their tumors in the progression category except for the EM-652-treated group, where only 7% of the tumors progressed. In the absence of estrone stimulation, progression was seen in 60%, 33%, 21% and 12% of tumors in the tamoxifen-, idoxifene-, toremifene- and raloxifene-treated groups, respectively, while only 4% of tumors progressed in the EM-652-treated group. The agonistic and antagonistic actions of each antiestrogen were also measured on endometrial epithelial cell thickness. Our present findings indicate that EM-652, in addition to being the most potent antiestrogen on human breast tumor growth, has no agonistic effect in breast and endometrial tissues. Since previous data have shown benefits of EM-652 on bone density and lipid profile, this compound could be an ideal candidate for chemoprevention of breast and uterine cancers, while protecting against osteoporosis and cardiovascular disease.
AuthorsMatthieu Gutman, Steeve Couillard, Jenny Roy, Fernand Labrie, Bernard Candas, Claude Labrie
JournalInternational journal of cancer (Int J Cancer) Vol. 99 Issue 2 Pg. 273-8 (May 10 2002) ISSN: 0020-7136 [Print] United States
PMID11979444 (Publication Type: Comparative Study, Journal Article)
CopyrightCopyright 2002 Wiley-Liss, Inc.
Chemical References
  • Cinnamates
  • Estrogen Antagonists
  • Piperidines
  • Stilbenes
  • Tamoxifen
  • droloxifene
  • 3-(4-(1,2-diphenylbut-1-enyl)phenyl)acrylic acid
  • Estrone
  • ritetronium
  • idoxifene
  • Raloxifene Hydrochloride
  • Toremifene
Topics
  • Animals
  • Breast Neoplasms (pathology)
  • Cell Division (drug effects)
  • Cell Size (drug effects)
  • Cinnamates (pharmacology)
  • Endometrium (drug effects)
  • Epithelial Cells (drug effects)
  • Estrogen Antagonists (pharmacology)
  • Estrone (administration & dosage, pharmacology)
  • Female
  • Humans
  • Kinetics
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Ovariectomy
  • Piperidines (pharmacology)
  • Raloxifene Hydrochloride (pharmacology)
  • Stilbenes (pharmacology)
  • Tamoxifen (analogs & derivatives, pharmacology)
  • Toremifene (pharmacology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: